Plus Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2025, on May 30, 2025. The company reported a net loss of $17.40 million for the quarter.
As of March 31, 2025, the company held $9.87 million in cash and cash equivalents and $3.53 million in investments, totaling $13.40 million in liquid assets. Current assets were $10.87 million, while current liabilities stood at $10.56 million, resulting in positive working capital of $0.31 million.
The company noted an improved cash position due to both a recent financing and ongoing grant support. Management stated that with this additional cash and anticipated grant support, the company is well-positioned to advance its REYOBIQ clinical trials and the planned launch of the CNSide cerebral spinal fluid assay platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.